# Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement

> **NCT03724084** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 6 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Cytarabine
- **DRUG:** Daunorubicin
- **DRUG:** Daunorubicin Hydrochloride
- **DRUG:** Pinometostat

## Key facts

- **NCT ID:** NCT03724084
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-10
- **Primary completion:** 2022-11-14
- **Final completion:** 2022-11-14
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Other - Study agent no longer available
- **Last updated:** 2025-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03724084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03724084, "Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03724084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*